Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users

Journal of Infectious Diseases

Volumn 203, Issue 9, 2011, Pages 1215-1221

  Milloy, M J ^a,b   Kerr, Thomas ^a,c   Buxton, Jane ^b,d   Rhodes, Tim ^e   Guillemi, Silvia ^a   Hogg, Robert ^a   Montaner, Julio ^a,c   Wood, Evan ^a,c,f  

^a ST PAUL S HOSPITAL   (Canada)

^b Centre for Health Services and Policy Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CANADA; COMMUNITY SAMPLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRISON; PRISONER; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRISONS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79954612445     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir032     Document Type: Article

References (46)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4. (Pubitemid 28082255)
2. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300:550-4.
3. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 2005;5:407-14. (Pubitemid 40840732)
4. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-74. (Pubitemid 37324254)
5. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004;35:261-8. (Pubitemid 38280651)
6. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205. (Pubitemid 30366625)
7. Shannon K, Bright V, Duddy J, Tyndall MW. Access and utilization of HIV treatment and services among women sex workers in Vancouver's Downtown Eastside. J Urban Health 2005;82:488-97. (Pubitemid 41191567)
8. Liu H, Longshore D, Williams JK, et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav 2006;10:279-86.
9. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med 2005;61:1026-44. (Pubitemid 40805548)
10. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy 2009;20:193-201.
11. Krusi A, Wood E., Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010;21:4-9.
12. Marlow E, White MC, Tulsky JP, Estes M, Menendez E. Recidivism in HIV-infected incarcerated adults: influence of the lack of a high school education. J Urban Health 2008;85:585-95.
13. Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009;166:103-9.
14. Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials 2007;8:205-12. (Pubitemid 47327457)
15. Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health 2006;96:974-8. (Pubitemid 43825263)
16. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One 2009;4:e7558.
17. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA 2009;301:848-57.
18. Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005;17:539-49. (Pubitemid 40979462)
19. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003;80:667-75. (Pubitemid 38146230)
20. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-65. (Pubitemid 27259515)
21. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003;17:887-93. (Pubitemid 36547661)
22. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-1. (Pubitemid 30327043)
23. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001;15:423-4. (Pubitemid 32163834)
24. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003;169:656-61. (Pubitemid 37266973)
25. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD41 cell count is 0.200 to 0.350 × 10 (9) cells/L. Ann Intern Med 2003;139:810-6.
26. Wood E, Montaner JS, Li K, et al. Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia. Am J Public Health 2008;98:515-9. (Pubitemid 351354521)
27. Wood E, Kerr T, Palepu A, et al. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infect 2006;52:233-6.
28. Aboriginal Issues Branch CSoC. Demographic overview of Aboriginal peoples in Canada and Aboriginal offenders in Federal corrections. Ottawa, Ontario: The Government of Canada, 1999.
29. Canadian Institutes of Health Research. CIHR guidelines for health research involving Aboriginal people. Ottawa, Ontario: Canadian Institutes of Health Research, 2007.
30. Wood E, Tyndall MW, Spittal PM, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ 2001;165:405-10. (Pubitemid 32885418)
31. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36. (Pubitemid 24002359)
32. Rothman KJ, Greenland S. Modern Epidemiology. New York, New York: Lippincott Williams & Wilkins, 1998.
33. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a populationbased cohort of HIV/AIDS patients. Soc Sci Med 2009;68:1044-9.
34. Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place 2009;15:753-60.
35. Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006;43:942-4. (Pubitemid 44435527)
36. Wood E, Kerr T, Hogg RS, Zhang R, Tyndall MW, Montaner JS. Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr 2006;41:530-1.
37. Krusi A, Milloy MJ, Kerr T, et al. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther 2010;15:789-96.
38. Tapp C, Milloy M-J, Kerr T, et al. Female gender predicts lower acess and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. In press.
39. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010;105:907-13.
40. Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005;17:539-49. (Pubitemid 40979462)
41. Palepu A, Tyndall MW, Chan K, Wood E, Montaner JSG, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004;9:713-9. (Pubitemid 39434334)
42. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003;80:667-75. (Pubitemid 38146230)
43. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004;38:1754-60. (Pubitemid 38781669)
44. Stephenson BL, Wohl DA, Golin CE, Tien H-C, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep 2005;120:84-8. (Pubitemid 40965708)
45. Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care 2009;21:708-14.
46. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health 2010;87:592-602.